iNtRON Biotechnology Inc Cash Flow Conversion Efficiency
iNtRON Biotechnology Inc cash flow conversion efficiency. Based on the latest financial reports, iNtRON Biotechnology Inc (048530) has a cash flow conversion efficiency ratio of -0.013x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-993.53 Million ≈ $-673.30K USD) by net assets (₩73.98 Billion ≈ $50.13 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of iNtRON Biotechnology Inc (2012–2024)
Cash flow conversion efficiency of iNtRON Biotechnology Inc from 2012 to 2024. This chart illustrates how iNtRON Biotechnology Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View 048530 share price today for real-time trading data and today's change.
iNtRON Biotechnology Inc Cash Flow Conversion Ratio Explained
iNtRON Biotechnology Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
iNtRON Biotechnology Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of iNtRON Biotechnology Inc ranked by their cash flow conversion efficiency. Also see 048530 stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
MHP HOTEL AG INH O.N.
F:CDZ0
|
N/A |
|
Seouleaguer Co. Ltd
KQ:043710
|
0.033x |
|
AurosTechnology Inc.
KQ:322310
|
0.037x |
|
ARRAS MINERALS CORP.
F:9RJ
|
-0.066x |
|
Travelzoo
NASDAQ:TZOO
|
-1.221x |
|
ActRO Co. Ltd
KQ:290740
|
0.101x |
|
N. B. I. Industrial Finance Company Limited
NSE:NBIFIN
|
0.002x |
|
Opter AB
ST:OPTER
|
0.230x |
Annual Cash Flow Conversion Efficiency for iNtRON Biotechnology Inc (2012–2024)
The table below shows the annual cash flow conversion efficiency of iNtRON Biotechnology Inc from 2012 to 2024. Review 048530 FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩83.77 Billion ≈ $56.77 Million |
₩-138.47 Million ≈ $-93.84K |
-0.002x | -105.13% |
| 2023-12-31 | ₩96.73 Billion ≈ $65.56 Million |
₩3.12 Billion ≈ $2.11 Million |
0.032x | -42.74% |
| 2022-12-31 | ₩106.18 Billion ≈ $71.96 Million |
₩5.98 Billion ≈ $4.05 Million |
0.056x | -65.37% |
| 2021-12-31 | ₩101.35 Billion ≈ $68.68 Million |
₩16.47 Billion ≈ $11.16 Million |
0.163x | +94.60% |
| 2020-12-31 | ₩85.38 Billion ≈ $57.86 Million |
₩7.13 Billion ≈ $4.83 Million |
0.084x | +767.82% |
| 2019-12-31 | ₩64.96 Billion ≈ $44.02 Million |
₩-812.48 Million ≈ $-550.61K |
-0.013x | -111.64% |
| 2018-12-31 | ₩39.09 Billion ≈ $26.49 Million |
₩4.20 Billion ≈ $2.85 Million |
0.107x | +159.44% |
| 2017-12-31 | ₩30.24 Billion ≈ $20.50 Million |
₩-5.47 Billion ≈ $-3.71 Million |
-0.181x | -91.32% |
| 2016-12-31 | ₩49.15 Billion ≈ $33.31 Million |
₩-4.64 Billion ≈ $-3.15 Million |
-0.094x | -291.53% |
| 2015-12-31 | ₩34.44 Billion ≈ $23.34 Million |
₩1.70 Billion ≈ $1.15 Million |
0.049x | +277.79% |
| 2012-12-31 | ₩11.93 Billion ≈ $8.08 Million |
₩-331.01 Million ≈ $-224.32K |
-0.028x | -- |
About iNtRON Biotechnology Inc
iNtRON Biotechnology, Inc. engages in the development of novel drugs in South Korea. It develops bacteriophage and endolysin based drugs. The company was founded in 1999 and is headquartered in Seongnam-si, South Korea.